Rapid normalization of interleukin-8 production after low-density lipoprotein apheresis in steroid-resistant nephrotic syndrome

Kidney International, Supplement

Volumn 56, Issue 71, 1999, Pages

  Sakurai, Mari ^b   Muso, Eri ^a   Matushima, Hiroyuki ^b   Ono, Takahiko ^b   Sasayama, Shigetake ^b  

^a KYOTO UNIVERSITY   (Japan)

^b NONE

Author keywords

FGS; Nephrotic syndrome; PBMC; TNF

Indexed keywords

INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; STEROID; TUMOR NECROSIS FACTOR ALPHA;

APHERESIS; CLINICAL ARTICLE; CONFERENCE PAPER; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; HUMAN; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; PROTEINURIA; TREATMENT OUTCOME; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; DRUG EFFECT; DRUG RESISTANCE; FEMALE; FOCAL GLOMERULOSCLEROSIS; MALE; MEMBRANOUS GLOMERULONEPHRITIS; METABOLISM; MONONUCLEAR CELL; PATHOLOGY;

BLOOD COMPONENT REMOVAL; CHEMOKINE CCL2; DRUG RESISTANCE; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; INTERLEUKIN-8; LEUKOCYTES, MONONUCLEAR; LIPOPROTEINS, LDL; MALE; NEPHROTIC SYNDROME; STEROIDS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033015642     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. MOORHEAD JF, CHAN MK, EL-NAHAS M, VARGHESE Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstilial disease. Lancet 11:1309-1311, 1982
2. KEANE WF, KASISKE BL, O'DONNELL MP, KIM Y: The role of altered lipid metabolism in the progression of renal disease: Experimental evidence. Am J Kidney Dis 17:38-42, 1991
3. THOMAS EM, HARRIS KPG, RAMASWAMY C, HATTERSLEY JM, WHEELER DC, VARGHESE Z, WILLIAMS JD, WALLS J, MOORHEAD JF: Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria. Kidney Int 44:1124-1129, 1993
4. MUSO E, YASHIRO M, MATUSHIMA M, YOSHIDA H, SAWANISHI K, SASAYAMA S: Does LDL- apheresis in steroid-resistant nephrotic syndrome affect prognosis? Nephrol Dial Transplant 9:257-264, 1994
5. HULTON SA, THOMAS JN, CALLARD RE, DILLON MJ, BARRATT TM: Circulating interleukin 2 receptor (IL2R) in nephrotic syndrome. Kidney Int 51(Suppl 58):S83-S84, 1997
6. GARIN FH, BLANCHARD DK, MATSUSHIMA K, DJEU JY: IL-8 production by peripheral blood mononuclear cells in nephrotic patients. Kidney Int 45:1311-1317, 1994
7. Muso E, MUNE M, FUJII Y, IMAI E, KINKI-FGS-LDL-APHERESIS TREATMENT (K-FLAT) STUDY GROUP: Significantly rapid induction to remission of steroid-resistant nephrotic syndrome (NS) by LDL apheresis (LDL-A): Multicenter control study. Nephrology 3(Suppl 1):S134, 1997
8. MUKAIDA N, OKAMOTO S, ISHIKAWA Y, MATUSHIMA K: Molecular mechanism of interleukin-8 gene expression. J Leukoc Biol 56:554-558, 1994
9. TERKELTAUB R, BANKA CL, SOLAN J, SANTORO D, BRAND K, CURTISS LK: Oxidized LDL induced monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler Thromb 14:47-53, 1994
10. SCHACKELFORD RE, MISRA UK, FLORINE CK, THAI SF, PlZZO SV, ADAMS DO: Oxidized low density lipoprotein suppresses activation of NF kappa B in macrophages via apertussis toxin- sensitive signaling mechanism. J Biol Chem 24:3475-3478, 1995